We boldly develop novel therapeutics utilizing cellular gene editing and complex cytokines

OUR FOCUS

Brooklyn ImmunoTherapeutics (BTX) is committed to creating a world in which patients and families with high unmet medical needs have access to effective treatments. To achieve this, we are focused on three primary approaches:

  • iPSC-derived, iMSC-based therapeutics
  • In vivo gene editing products
  • IRX-2, a human cell-derived (hd) IL-2 therapeutic

LATEST NEWS

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

[ READ MORE ]

Brooklyn ImmunoTherapeutics Appoints 
Roger Sidhu, M.D. as Chief Medical Officer

[ READ MORE ]

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

[ READ MORE ]

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET

[ READ MORE ]

LATEST PRESENTATION